Drug distribution becomes weapon to block competition

WASHINGTON -- The same strategy that Martin Shkreli used to get away with a 5,000-per cent price increase on an old drug is used by many other drugmakers to maintain sky-high prices on billions of dollars' worth of medications.

See Full Article

Before the price hike that made him infamous, the former CEO of Turing Pharmaceuticals had to ensure that no competitor would be able to launch a cheaper version of Daraprim, the 60-year-old anti-infection pill that is no longer under patent.

Shkreli had the perfect weapon: a tightly-controlled distribution system which would make it virtually impossible for a competitor to obtain enough Daraprim to develop their own version.

Shkreli, who resigned in December, did not invent the closed distribution technique. And his former company, Turing, notes that Daraprim was already distributed under such a system when it acquired the drug.

Many larger drugmakers have also turned drug distribution into a powerful tool against competition. The strategy takes advantage of a simple fact: If generic drugmakers can't get their hands on the original product, they cannot perform the tests needed to develop a generic version. Typically generic drugmakers purchase drugs in bulk from third-party suppliers. But when the original drugmaker controls the drug's distribution, they can simply refuse to sell.

The effect on patients is higher prices for drugs that would otherwise be available as low-cost generics. Doctors say these tactics "continue to stand in the way of patients' access."

"The most effective way to improve access and lower prices is to ensure that generic drugs get to market as quickly as possible," says Dr. Ameet Sarpatwari, of Harvard Medical School, who has studied the issue.

At least 40 drugs worth an estimated $5.4 billion are sheltered from competition by distribution hurdles, according to a study commissioned by the Generic Pharmaceutical Association, an industry trade group.

The Food and Drug Administration is aware of the misuse of distribution programs. The agency said in a statement it has received 100 letters from companies that say they have been blocked from obtaining drugs for testing purposes. The agency's own regulations prohibit drugmakers from using certain types of distribution plans to block generic access, but the agency does not penalize companies for the practice.

The trend began in 2007, when the FDA began requiring risk-management plans for certain drugs. The plans often feature various restrictions to make sure drugs are used safely, including limits on who can distribute them. But drugmakers realized these measures could also be used to keep their drugs away from competitors. And even drugs that didn't require risk-management could utilize the strategy.

Daraprim is an example of a drug that has no major safety risks and was previously available through various wholesalers and distributors. But last June - three months before its sale to Turing - Daraprim was moved into a closed distribution program, allowing the manufacturer to refuse sales to competitors.

The effect for patients was jarring. The drug - which treats an infection mainly found in people with HIV and cancer - had previously been available through local pharmacies. Now it is distributed through a specialty division of Walgreen's, which sells the drug at Turing's list price of $750 per pill. In the months after the price hike, some patients faced co-pays as high as $16,000 when trying to fill a prescription.

"Mr. Shkreli set up a very complicated system to ensure profits and patients have really suffered," says Sean Dickson, of the National Alliance of State and Territorial AIDS Directors.

Turing says it has improved access to Daraprim, including making it available through a patient assistance program for those that can't afford it.

Drugmakers argue that closed distribution simply protects their interests, making sure drugs are shipped and handled appropriately.

But generic drugmakers say the tactics threaten their business model.

"It undermines the whole generic drug approval process," said Steve Giuli, an executive with generics firm Apotex Corp.

Apotex has repeatedly tried to purchase two specialty cancer drugs sold by drugmaker Celgene. Together the drugs, Thalomid and Revlimid, account for $5.2 billion in sales, more than two-thirds of Celgene's revenue for 2014. That's the despite the fact that Thalomid is a 1950s-era drug whose key ingredient is no longer under patent. Because the drug can cause severe birth defects, it is subject to a rigorous distribution program controlled by Celgene.

"They will never freely sell you the product, even if you negotiate with them for weeks, months, and perhaps years to satisfy all of their onerous concerns," says Omar Jabri, another Apotex executive.

A Celgene spokesman did not return calls and emails seeking comment on the risk-management program.

In one case, New Jersey-based Celgene went on the offensive, suing Barr Laboratories for attempting to introduce a generic version of Thalomid. Celgene said Barr's effort would infringe on its intellectual property, since it had patented Thalomid's risk-management plan.

When generic drugmaker Lannett sued Celgene in 2012, alleging that the company's tactics illegally blocked competition, the companies reached an out-of-court settlement. Details of the agreement were not disclosed but Thalomid remains unavailable as a generic.

Meanwhile, the FDA has remained on the sidelines.

"The FDA is hesitant to make a call on whether a manufacture is actually intending to delay generic competition," explains pharmaceutical attorney Kurt Karst.

With no apparent solution from the courts or the FDA, generic drugmakers and their allies are seeking a fix from Congress.

A bill introduced in the House would direct the FDA to impose stiff fines on drugmakers that refuse to sell their products to generic drugmakers.

Introduced last summer, the legislation has made little headway on Capitol Hill, but Dr. Sarpatwari hopes recent concerns about drug prices will attract more attention to the proposal.

"You're getting Congress to amend the system to require that drug samples be shared under the penalty of actual sanctions," he says. "That's ultimately where we need to get to."



Advertisements

Latest Economic News

  • Graduating? 5 tips from a millennial on taking control of your debt

    Economic CTV News
    High financial expectations coupled with harsh employment realities have left recent post-secondary graduates feeling a little anxious and overwhelmed. According to TD, the competitive job market, lower than anticipated income and higher than expected costs are just some of the realities facing post-secondary graduates. Source
  • Greece looks for debt help after backing further cuts

    Economic CTV News
    BRUSSELS -- Greece is seeking Monday to persuade its creditors in Europe that it has done enough to get another chunk of bailout loans and a firm commitment on alleviating Athens' hefty debt burden. Greek Finance Minister Euclid Tsakalotos is meeting his counterparts from the 19-country eurozone at a meeting in Brussels, where Greece will once again be top of the agenda. Source
  • Concerns over housing, indebted consumers weigh on banks as they report Q2 results

    Economic CTV News
    TORONTO -- The Canadian banks are expected to benefit from rising U.S. interest rates and fewer bad loans in the oilpatch as they start reporting their latest quarterly results this week, but analysts say worries about the housing market and consumer debt remain key concerns. Source
  • Australian iron ore magnate donates $300 million to charity

    Economic CTV News
    CANBERRA, Australia -- Iron ore mining magnate Andrew Forrest said Monday he was donating 400 million Australian dollars (US$300 million) to charities in what has been described as a new record in Australian philanthropy. Forrest, the 55-year-old chairman of Fortescue Metal Group, and his wife, Nicola, announced the money will be spent on cancer research, Australian university research, supporting disadvantaged people including Aborigines, and fighting slavery around the world. Source
  • Chinese online retailer developing one-ton delivery drones

    Economic CTV News
    BEIJING -- China's biggest online retailer, JD.com Inc., announced plans Monday to develop drone aircraft capable of carrying a ton or more for long-distance deliveries. The company said it will test the drones on a network it is developing to cover the northern Chinese province of Shaanxi. Source
  • Germany, France pledge new effort to strengthen eurozone

    Economic CTV News
    BERLIN -- Germany and France pledged Monday to seek ways to strengthen the eurozone, with harmonization of corporate taxes among possible measures that they will mull in the coming weeks. German Finance Minister Wolfgang Schaeuble and new French counterpart Bruno Le Maire said they are setting up a working group to produce proposals for a planned bilateral summit in July. Source
  • Ford replaces CEO in push to transform business

    Economic CBC News
    Ford Motor Co. is replacing CEO Mark Fields amid questions about its current performance and future strategy, according to a person familiar with the situation. Ford to cut 1,400 jobs by the end of this summer Source
  • Ford replaces CEO Mark Fields in push to transform business

    Economic CBC News
    Ford is replacing CEO Mark Fields as it struggles to keep its traditional auto-manufacturing business running smoothly while remaking itself as a nimble, high-tech provider of new mobility services. Ford to cut 1,400 jobs by the end of this summer Source
  • Asian stocks track Wall Streets rally despite global worries

    Economic CTV News
    TOKYO - Asian stocks rose Monday, cheered by the latest rally on Wall Street and relative quiet in American politics as U.S. President Donald Trump began his first official trip overseas as president. KEEPING SCORE: Japan's benchmark Nikkei 225 gained 0.4 per cent to 19,673.17. Source
  • Cathay Pacific laying off 600 as it blames 'rising pressure'

    Economic CTV News
    Hong Kong airline Cathay Pacific Airways said Monday it's laying off nearly 600 staff at its headquarters as it faces rising competition from rival carriers and tough business conditions. The airline said it plans to axe about 190 managers, or a quarter of all the company's management jobs. Source